Global Blood Therapeutics Trades Higher, Sickle Cell Therapy Data
Yesterday, Global Blood Therapeutics (GBT), a clinical-stage biopharmaceutical company, announced positive top-line data for its Phase 3 HOPE study of its Voxelotor therapy for sickle cell disease. GBT stock rose by ~15.6% yesterday and was up ~3.7% in pre-market trading today.